Volanesorsen
Waylivra (volanesorsen) is an oligonucleotide pharmaceutical. Volanesorsen was first approved as Waylivra on 2019-05-03. It has been approved in Europe to treat hyperlipoproteinemia type i.
| Trade Name | Waylivra |
|---|---|
| Common Name | Volanesorsen |
| Indication | hyperlipoproteinemia type i |
| Drug Class | Antisense oligonucleotides |
